Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced β-catenin activation.
Aging
/ metabolism
Animals
Aorta
/ pathology
Biomarkers
/ metabolism
Cardiomegaly
/ metabolism
Complement C1q
/ metabolism
Constriction, Pathologic
Male
Mice, Inbred C57BL
Mice, Knockout
Myocardium
/ metabolism
Myocytes, Cardiac
/ metabolism
Phenotype
Pressure
Progranulins
/ deficiency
Rats
Signal Transduction
beta Catenin
/ metabolism
Age-related cardiac hypertrophy
Complement C1q
Progranulin
Senescence
β-Catenin
Journal
Journal of molecular and cellular cardiology
ISSN: 1095-8584
Titre abrégé: J Mol Cell Cardiol
Pays: England
ID NLM: 0262322
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
14
07
2019
revised:
15
11
2019
accepted:
17
12
2019
pubmed:
24
12
2019
medline:
22
1
2021
entrez:
24
12
2019
Statut:
ppublish
Résumé
Age-related cardiac hypertrophy and subsequent heart failure are predicted to become increasingly serious problems in aging populations. Progranulin (PGRN) deficiency is known to be associated with accelerated aging in the brain. We aimed to evaluate the effects of PGRN deficiency on cardiac aging, including left ventricular hypertrophy. Echocardiography was performed on wild-type (WT) and PGRN-knockout (KO) mice every 3 months from 3 to 18 months of age. Compared to that of WT mice, PGRN KO mice exhibited age-dependent cardiac hypertrophy and cardiac dysfunction at 18 months. Morphological analyses showed that the heart weight to tibia length ratio and cross-sectional area of cardiomyocytes at 18 months were significantly increased in PGRN KO mice relative to those in WT mice. Furthermore, accumulation of lipofuscin and increases in senescence markers were observed in the hearts of PGRN KO mice, suggesting that PGRN deficiency led to enhanced aging of the heart. Enhanced complement C1q (C1q) and activated β-catenin protein expression levels were also observed in the hearts of aged PGRN KO mice. Treatment of PGRN-deficient cardiomyocytes with C1q caused β-catenin activation and cardiac hypertrophy. Blocking C1q-induced β-catenin activation in PGRN-depleted cardiomyocytes attenuated hypertrophic changes. Finally, we showed that C1 inhibitor treatment reduced cardiac hypertrophy and dysfunction in old KO mice, possibly by reducing β-catenin activation. These results suggest that C1q is a crucial regulator of cardiac hypertrophy induced by PGRN ablation. The present study demonstrates that PGRN deficiency enhances age-related cardiac hypertrophy via C1q-induced β-catenin activation. PGRN is a potential therapeutic target to prevent cardiac hypertrophy and dysfunction.
Identifiants
pubmed: 31866375
pii: S0022-2828(19)30399-2
doi: 10.1016/j.yjmcc.2019.12.009
pii:
doi:
Substances chimiques
Biomarkers
0
Progranulins
0
beta Catenin
0
Complement C1q
80295-33-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-211Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None declared